{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T17:28:29Z","timestamp":1788629309581,"version":"build-2803163510"},"reference-count":0,"publisher":"The Medical Letter, Inc.","issue":"1706","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Lett Drugs Ther"],"abstract":"<jats:p>Trofinetide (Daybue \u2013 Acadia), a synthetic analog of glycine-proline-glutamate, has been approved by the FDA for treatment of Rett syndrome in patients \u22652 years old. It is the first drug to be approved in the US for treatment of Rett syndrome.<\/jats:p>","DOI":"10.58347\/tml.2024.1706d","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T15:17:28Z","timestamp":1723735048000},"page":"e115-e116","source":"Crossref","is-referenced-by-count":2,"title":["Trofinetide (Daybue) for Rett Syndrome"],"prefix":"10.58347","volume":"66","author":[{"name":"Editors from The Medical Letter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"37151","published-online":{"date-parts":[[2024,7,8]]},"container-title":["The Medical Letter on Drugs and Therapeutics"],"original-title":[],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T15:17:28Z","timestamp":1723735048000},"score":1,"resource":{"primary":{"URL":"https:\/\/secure.medicalletter.org\/TML-article-1706d"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":0,"journal-issue":{"issue":"1706","published-online":{"date-parts":[[2024,7,8]]}},"URL":"https:\/\/doi.org\/10.58347\/tml.2024.1706d","relation":{},"ISSN":["1523-2859"],"issn-type":[{"value":"1523-2859","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]}}}